Megan Blewett is the co-founder and Vice President of Corporate Development at Iris Medicine, a Venrock-backed therapeutics company. She also co-founded Kelonia Therapeutics, which is engineering novel lentiviruses to achieve tissue-specific delivery of gene therapies. Megan was previously an investor at Venrock, where she worked on the launch of Federation Bio, a microbiome company developing bacterial consortia to treat serious metabolic and immune diseases.

Prior to Venrock, Megan earned a PhD in chemistry as a Hertz Fellow and NSF Fellow with Benjamin Cravatt at The Scripps Research Institute. Her PhD work helped form the foundation of the biotech company Vividion (acq. by Bayer for $1.5B in 2021). Megan received her undergraduate degree in chemistry from Harvard, where she worked for Nobel Laureate EJ Corey. Megan has been named to the Forbes 30 under 30 list for Healthcare and Business Insider’s Under 40 in Biotech.